Ticagrelor and platelet reactivity in acute coronary syndromes

Phase 4

• Conditions: Acute Coronary Syndrome; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12613001208796
• Lead Sponsor: Peter Larsen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Acute coronary syndrome

Exclusion Criteria

Known platelet function disorder
Platelet count less than 100
Prior administration of a P2Y12 receptor antagonist within 2 weeks

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of platelet inhibition measured using platelet impedance aggregometry at 2 hours (using Multiplate system).[2 hours after loading dose]

Secondary Outcome Measures

Name	Time	Method
evel of platelet inhibition measured using platelet impedance aggregometry at 1, 4 and 8 hours (using Multiplate system).[at 1 hour, 4 hours and 8 hours after loading dose]